Opening Remarks

  • W. L. Holmes
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 26)


In opening this Symposium on Drugs Affecting Lipid Metabolism, I thought it might be of interest to reflect for a moment on some of the past developments in this field. It was in 1931, exactly 40 years ago, that Dr. Paul Dudley White published the first edition of his celebrated book entitled “Heart Disease.” In discussing the treatment of arterial disease, Dr. White said the following concerning arteriosclerosis: “For arteriosclerosis itself there is as yet no known therapy; some believe that the agelong use of potassium iodide or other drug of traditional value may some day prove to have a scientific basis. If the condition is rapidly progressive or pronounced, it is probably wise to prevent overexertion, overeating, and overexposure to infections without restricting too much the activities of life which in themselves favor health and happiness.” Since that time, and particularly during the past twenty years, we have witnessed a tremendous explosion in the development of new basic knowledge concerning many facets of atherosclerosis, which in turn have led to new approaches to its treatment and even to its prevention. Testimony to this is seen in the ever increasing literature devoted to either the nutritional-hygenic or pharmacological approaches to the control of atherosclerotic vascular disease.


Arterial Disease Pharmacological Approach Cholesterol Biosynthesis Potassium Iodide Program Committee 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science+Business Media New York 1972

Authors and Affiliations

  • W. L. Holmes
    • 1
  1. 1.Division of ResearchLankenau HospitalPhiladelphiaUSA

Personalised recommendations